Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


King Plans Skelaxin “Authorized” Generic When Metaxalone ANDAs Launch

This article was originally published in The Pink Sheet Daily

Executive Summary

King will launch an "authorized" generic of Skelaxin (metaxalone) when ANDA versions of the muscle relaxant enter the market

You may also be interested in...

Sepracor Insomnia Spot Suggests Lunesta “Product And Use” Ads Coming Soon

The unbranded spot tells patients suffering from insomnia to stay tuned for more information coming April 24 about “something on its way that could change your nights.” The ad first aired April 10. Sepracor is also planning to discuss labeling revisions with FDA based on its second six-month trial.

Skelaxin Generics May Launch Before July 2005: FDA To Allow Labeling "Carve Out"

The agency says ANDA filers Eon and Corepharma may delete protected labeling on food effects covered by King’s method-of-use patent.

Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial

The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts